Review Article

Current Management of Childhood Amblyopia

Shin Hae Park

Department of Ophthalmology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea

Amblyopia is defined as the reduction of best-corrected visual acuity of one or both eyes caused by conditions that affect normal visual development. The basic strategy to treat amblyopia is to obtain a clear retinal image in each eye and correct ocular dominance through forced use of the amblyopic eye. Treatment modalities include correcting any underlying organic disease, prescribing appropriate optical correction, and providing occlusion/penalization therapy for the non-amblyopic eye. Given the success of amblyopia treatment declines with increasing age, the detection and management of amblyopia should begin as early as possible during the sensitive period for visual development. Proper management of amblyopia during childhood can reduce the overall prevalence and severity of visual loss. This study aims to provide an update for the management of childhood amblyopia to provide better visual outcomes.

Key Words: Amblyopia, Optical correction, Patching, Pharmacologic treatment

Introduction

Amblyopia is the most common cause of preventable visual disability in children, occurring in approximately 2% to 5% of the general population [1]. Generally, amblyopia refers to the reduction of best-corrected visual acuity (BCVA) in one or both eyes that cannot be exclusively attributed to a structural abnormality of the eye. Poor vision caused by structural abnormalities of the eye and brain (such as congenital cataracts, optic nerve atrophy, retinal dystrophy, or anoxic brain damage) is regarded as organic amblyopia. Amblyopia interrupts normal visual pathway development during childhood. Amblyopia can be reversed when appropriate visual stimulation is provided within the sensitive period of visual development.

Normal Visual Development and Vision Screening

Amblyopia is caused by abnormal visual processing early in life. Visual acuity (VA) at birth is poor due to the immaturity of visual processing. Appropriate visual stimulation, including clear retinal images, equal image clarity in both eyes, and proper ocular alignment are needed for normal visual development. VA improves rapidly during the first few months of life as clear retinal images begin to stimulate neurodevelopment of visual centers [2,3]. Although the length of the critical period for visual development is somewhat controversial, it is generally considered to be from birth to 3 months of age [2,3]. Visual development continues until 7 to 8 years of age (sensitive period)
and neural plasticity for visual development is progressively reduced in late childhood [2-4].

Children under 7 years of age who are not provided appropriate visual stimulation are vulnerable to amblyopia, and the earlier the onset of abnormal visual stimulation, the greater the visual deficit. Children should therefore be screened for vision problems and properly treated early in their life [5,6]. In South Korea, a nationwide infant and toddler vision screening program was initiated in 2008 as a part of the Infant Health Screening Project of the Korean National Health Insurance Corporation [7]. The program screens children aged 4 months to 6 years for the presence of frequent and important ocular problems. Unilateral or bilateral vision problems, strabismus, and refractive errors are important target diseases for vision screening in childhood.

**Diagnosis and Classification of Amblyopia**

Abnormal visual stimulation by a unilateral or bilateral blurred retinal image or a misalignment of two eyes can lead to permanent damage to the visual processing to the visual center in the brain. The diagnosis of amblyopia requires detection of decreased VA and identification of the cause associated with the visual problem. Amblyopia rarely develops in the absence of strabismus, unequal refractive error, media opacity, or other ocular and neural abnormalities. When the cause for the visual deficit is not obvious, clinicians should search for a possible alternative diagnosis that predisposed the child to decreased vision. Bilateral amblyopia is usually diagnosed when BCVA is worse than 20 / 50 in children aged ≤4 years, <20 / 40 in children aged 4 to ≤5 years, or <20 / 30 in children aged >5 years [1]. Unilateral amblyopia is defined clinically as a between-eye difference in BCVA of 2 or more lines [1]. Anisometropia and strabismus are the two main amblyogenic factors, and some children have combined anisotropic-strabismic amblyopia. Amblyopia is generally classified as follows: strabismic (misalignment of the visual axis), refractive, anisometropia (difference in refraction of the two eyes), isoametropic (bilateral high refractive error), visual deprivation (media opacity, ptosis, etc.), and occlusion.

**Treatment of Amblyopia**

The basic strategy to treat amblyopia is to provide a clear retinal image to each eye and correct ocular dominance. Treatment modalities include correcting any underlying organic disease, prescribing appropriate optical correction, and providing occlusion/penalization therapy for the dominant eye within the sensitive period of visual development. Amblyopia treatment can effectively restore normal or near-normal visual function by eliminating eccentric fixation and/or developing more extensive synaptic input to the visual cortex [8,9]. Detection and management of amblyopia should be initiated as early as possible during the sensitive period for visual development because the success of amblyopia treatment decreases with increasing age [5-7,10,11].

The Pediatric Eye Disease Investigator Group (PEDIG) is a clinical network of pediatric ophthalmologists funded by the US National Eye Institute to conduct clinical research studies related to pediatric eye disorders. The Amblyopia Treatment Studies conducted by PEDIG have focused on evaluating the effectiveness and duration of different amblyopia treatment modalities for children and adolescents. Their results have provided an evidence-based treatment approach and changed clinical practice guidelines for children with amblyopia. Many pediatric ophthalmologists now follow the current recommendations suggested by the PEDIG. This review is mainly based on the results from PEDIG studies. We also searched for other clinical studies for amblyopia and describe the results in this review.

**Optical correction**

Optical correction of refractive error is the initial step to provide a clear retinal image to each eye for children with amblyopia. A guideline for consideration of refractive correction for children is described in the Preferred Practice Pattern guidelines published by the American Academy of Ophthalmology in 2018 [12]. Optical correction should be tailored to the individual child together with consideration of the findings of the clinical examination, visual symptoms, and patient history.

A PEDIG trial has investigated the effect of spectacle correction on bilateral refractive amblyopia in children aged 3 to less than 10 years with BCVA of 20 / 40 to 20 /
400 without previous treatment [13]. Spectacle correction resulted in improvement of binocular BCVA: 73% of children achieved VA of 20 / 25 or better within one year of starting treatment; binocular VA improved by an average of 3.9 lines and children with worse baseline VA had greater improvement in terms of the number of lines; however, the probability of achieving 20 / 25 or better binocular VA was greater in children who had better baseline VA [13]. Some studies have suggested that spectacle correction alone can be used as a treatment for anisometric amblyopia [14,15]. Refractive correction alone improved VA by ≥2 lines in 77% of patients and resulted in resolution of amblyopia in at least one third of children aged 3 to 7 years who had untreated anisometric amblyopia [15]. Most cases where resolution was reported with refractive correction alone had moderate (20 / 40 to 20 / 100) amblyopia. For children with greater degrees of amblyopia, initial treatment with spectacles resulted in a 3-line improvement in VA on average, which may have reduced the burden of subsequent amblyopia therapy. In addition, a study of children aged 7 to 17 years found that amblyopia improved by 2 or more lines with optical correction alone in about one fourth of children enrolled [16]. The effects of spectacle correction on strabismic amblyopia have also been investigated [17,18]. Refractive correction with spectacles alone resulted in a clinically meaningful improvement in VA in the amblyopic eye in the majority of previously untreated strabismic children. Overall, a mean improvement of 2.6 lines occurred in the amblyopic eye, with 75% of children showing improvement of ≥2 lines and 54% of children showing improvement of ≥3 lines. Resolution of amblyopia occurred in 32% of patients [17].

Patching

Patching or occlusion therapy involves covering the sound eye to stimulate the amblyopic eye. It has been the mainstay of amblyopia treatment for the past 250 years. Patching is currently the preferred treatment option among ophthalmologists, although other methods such as atropine penalization have been shown to provide equivalent remediation for moderate and severe amblyopia [1,10,11].

Over the last decade, several randomized controlled clinical trials have provided evidence as to how to tailor amblyopia therapy more precisely to achieve the best visual outcome while minimizing negative impacts on children and their family. There have been many studies on the number of hours of patching per day [19-23]. In a PEDIG trial, 6 hours per day occlusion treatment produced an improvement of VA that was of similar magnitude to that obtained by full-time occlusion in children 3 to less than 7 years of age with severe amblyopia (20 / 100 to 20 / 400) [19]. In children who had moderate amblyopia (20 / 40 to 20 / 80), initial occlusion therapy for 2 hours daily resulted in an improvement in VA that was similar in magnitude to the improvement produced by prescribing 6 hours of daily patching [20]. After 17 weeks of treatment, children with severe amblyopia showed a mean improvement of 3.6 lines with 2 hours of daily patching [21]. For children with residual amblyopia after treatment with refractive correction and 2-hour patching, increasing the daily patching time to 6 hours resulted in an average of 1.2 lines of statistically significant additional improvement at 10 weeks, compared to an average 0.5 line additional improvement when continuing with just 2 hours of patching [22]. Improvement of ≥2 lines occurred in 40% of participants after patching for 6 hours versus 18% of those who continued 2-hour patching. When vision in the amblyopic eye stops improving with two hours of daily patching, increasing the daily patching duration to 6 hours is recommended to obtain greater improvement in VA [22,23]. Patching should be considered even in older children and teenagers, particularly if they have not been previously treated [10,16,24]. For patients aged 7 to 17 years, prescribing 2 to 6 hours per day of patching together with near visual activities can improve VA even if the amblyopia has been previously treated [16].

Clinicians should be aware that children treated with patching may develop occlusion amblyopia or strabismus. Amblyopia patients who had previously been treated with patching were found to have deterioration and improvement of ocular alignment [25,26]. Parents should be informed that change in ocular alignment may occur in some amblyopia patients after patching.

Atropine penalization

Penalization using atropine produces cycloplegia in the non-amblyopic eye. It is an effective choice for treating children who do not show improvement with spectacles alone. Atropine (1%) eye drops lead to loss of accommodation and optical defocusing in the non-amblyopic eye and
forced use of the amblyopic eye. Atropine is most effective when the non-amblyopic eye is hyperopic. The importance of a fixation switch to the amblyopic eye has been considered an important predictor of success with atropine penalization [27,28].

PEDIG trials have compared patching and atropine as treatments for moderate amblyopia [27-30]. Both atropine penalization and patching were effective treatments for children with moderate amblyopia. VA improved by 3.16 lines in the patching group and 2.84 lines in the atropine group after 6 months of treatment in children younger than 7 [29]. Although improvement was initially more rapid in the patching group, the between-group difference in VA was small and statistically non-significant after 6 months [29]. A PEDIG trial that enrolled children from 3 to 12 years of age with severe amblyopia (20 / 125 to 20 / 400) found that their vision also improved with weekend atropine [31].

Atropine is initially prescribed daily for amblyopia treatment. The cycloplegic effect of topical atropine usually lasts for several days. Less frequent dosing of atropine may enhance compliance with treatment. Several studies have investigated daily use and weekend use of atropine for amblyopia treatment [32,33]. A study by Simons et al. [32] has reported that intermittent atropine therapy (one or two days a week) is as successful as daily atropine therapy. The first prospective clinical trial by PEDIG found that the magnitude of improvement after 4 months of treatment was 2.3 lines with both daily and weekend atropine regimens [27]. Prescribing weekend atropine appeared to be as effective as daily atropine in treating children with moderate amblyopia [27]. Weekend atropine seems to be equally effective and produces greater compliance. It should be noted that atropine had less pronounced dilating and cycloplegic effects in children with dark iris pigmentation [33,34]. When initiated before age 7, improvement achieved with patching or atropine treatment for moderate amblyopia due to strabismus, anisometropia, or both was maintained until 10 to 15 years of age in children with a mean VA in their amblyopic eye of about 20 / 25 [35].

Amblyopia treatment in older children

Although it is true that amblyopia can be treated more effectively in younger children, several studies have shown that older children and adults with amblyopia are also able to respond to amblyopia treatment [4,10,16,24,36-40]. A randomized PEDIG trial assessing treatment of amblyopia in children aged 7 to 17 years [16] revealed the following results: (1) amblyopia improved with optical correction alone in about one fourth of patients aged 7 to 17 years, (2) for patients aged 7 to 12 years, 2 to 6 hours per day of patching together with near visual activities and atropine improved VA even if the amblyopia had been treated previously, (3) even for patients 13 to 17 years of age, patching for 2 to 6 hours per day together with near visual activities improved VA when amblyopia had not been treated previously. A recent analysis of the Preferred Practice Pattern for amblyopia by the American Academy of Ophthalmology recommended treatment for children up to 10 years of age [1].

Compliance with prescribed amblyopia treatment

Compliance is defined as the extent to which a patient’s behavior matches the prescribed treatment. Many studies have demonstrated that treatment compliance is the most critical factor for predicting a successful outcome in amblyopic children [41,42]. Reported rates of compliance with prescribed treatment range widely. Compliance with amblyopia therapy may be improved by educational programs or more effective communication with children and their parents. Poor parental knowledge has been reported to be associated with poor compliance [42-44]. A study by Newsham [44] reported that a large proportion of patients could benefit by increasing parental knowledge in several key areas, such as critical period, importance of amblyopia therapy, and potential negative consequences of not treating amblyopia. Written information may be a simple, inexpensive, and effective method to improve parental understanding of amblyopia and subsequent compliance of their children with prescribed treatment/s. Increasing the frequency of physician check-up and a more direct communication between physician and child can also contribute to improved compliance with treatment and better final visual outcome [41]. Beginning therapy with a less intensive patching regime can also help improve patient compliance [20-23]. Splitting part-time patching hours into 2 or more smaller sessions has been reported to provide visual improvement comparable to equivalent numbers of continuous hours of part-time patching for children with anisometropic amblyopia while creating less emotional stress [45].
Patching is usually administered by applying an opaque adhesive patch directly to the skin surrounding the non-amblyopic eye. Periocular skin irritation due to adhesive skin patches during amblyopia treatment can cause considerable distress and reduce compliance with treatment. A recent study has shown that treatment with either adhesive skin patching or over-glasses patching produced similar degrees of vision improvement of the amblyopic eye [46].

**New Treatments for Amblyopia**

Alternative therapies for amblyopia treatment have long been a topic of interest among researchers and clinicians. New technologies have been incorporated into standard therapy for amblyopia as our understanding of the pathophysiological basis of amblyopia has increased.

**Intermittent occlusion glasses**

With regard to advances in occlusion therapy for amblyopia, an electronic device, Amblyz liquid crystal intermittent occlusion glasses (XPAND 3D Group, Ljubljana, Slovenia), has been introduced. Intermittent occlusion glasses are programmed to unilaterally alternate between opaque and transparent phases at 30-second intervals, providing effective occlusion of the fellow eye 50% of the time they are worn. Because these glasses are more child friendly and do not produce the side effects seen with adhesive skin patches, they may potentially improve compliance with occlusion therapy. However, a recent study to monitor objective compliance with intermittent occlusion glasses using a microsensor affixed to the glasses found that general compliance was not as high as was anticipated for this new technology (averaging 51.6%) and varied greatly from patient to patient (range, 10% to 97%), and in addition, daily compliance decreased slightly over time [47]. There have been several studies assessing the effectiveness of the intermittent occlusion glasses [48-50]; however, there has been only one randomized clinical trial comparing the effectiveness of liquid crystal occlusion glasses and adhesive occlusion patches [50]. After 12 weeks of treatment, 4 hours’ daily intermittent occlusion therapy with liquid crystal glasses was not inferior to 2 hours’ daily patching when treating children 3 to 8 years of age with moderate, unilateral amblyopia [50]. However, there have been no further studies to confirm the effectiveness of intermittent occlusion therapy glasses, in terms of age, severity and subtype of amblyopia.

**Perceptual learning**

Perceptual learning refers to any relatively permanent and consistent change in the perception of a sensory task following repeated practice [51,52]. Visual performance may be improved with repetitive practice of specific controlled visual tasks. Persistence of binocular cortical communication in subjects with amblyopia is the basis for the hypothesis that activation of these persistent binocular neural circuits might awaken an amblyopic eye. Since the Cambridge Stimulator treatment described in the 1970s, which was the first application of perceptual learning theory to amblyopia [53], perceptual learning to various visual tasks has resulted in improvement in orientation discrimination, stereoaucity and contrast sensitivity, even in adults with amblyopia [54-56]. Perceptual learning seems to be a promising method; however, small numbers of participants in the previously published studies and lack of long-term follow-up currently limit widespread use of perceptual learning as a therapeutic option for amblyopia.

**Dichoptic training**

It has been suggested that patching may further disrupt binocularity and theoretically may not be an ideal method to restore binocular cortical function in amblyopic patients [57-64]. Binocular visual stimulation using computer games played on a smartphone or computer tablet has been suggested as a means to improve not only VA, but also binocular function [57-64]. Dichoptic presentation refers to presenting different images to each eye. Given the amblyopic eye has lower contrast sensitivity compared to the sound eye, when employing dichoptic presentation as a treatment method, children with amblyopia are trained on tasks in which reduced contrast images are presented to the sound eye while higher contrast images are shown to the amblyopic eye in order to balance cortical input and overcome inter-ocular suppression. Early non-randomized studies of binocular visual stimulation have demonstrated promising results [59-61]. Recently, several clinical trials employing different testing protocols and different age
groups with or without prior amblyopia treatment have been completed to investigate the effectiveness of binocular computer tablet treatment for amblyopia [60-64]. A PEDIG trial has compared VA improvement in children with amblyopia treated with a binocular iPad game for 1 hour a day vs. part-time patching for 2 hours a day in 385 children aged 5 to 12 years with amblyopia [60]. At 16 weeks, mean amblyopic-eye VA improved 1.05 lines in the binocular group and 1.35 lines in the patching group, with an adjusted treatment group difference of 0.31 lines (favoring patching). Binocular treatment of amblyopia using videogames (BRAVO) has been performed to compare the effectiveness of a binocular video game with a placebo video game for improving visual functions [64]. The results indicated that the binocular video game did not improve visual outcomes more than the placebo video game in older children and adults [64]. In children aged 13 to 16 years, improvement in amblyopic eye VA with a binocular iPad game was not better than patching [62]. There was no benefit with respect to VA or stereoaucity after 4 or 8 weeks of treatment with the dichoptic binocular Dig Rush iPad game in children aged 7 to 12 years who had received no previous treatment for amblyopia other than spectacles [63]. Although research has been ongoing, to date, evidence supporting the inclusion of binocular treatment for amblyopic patients remains insufficient.

Transcranial magnetic stimulation

Transcranial magnetic stimulation (TMS) is an established, safe, and noninvasive technique for stimulating the human brain. The technique is based on the principle of electromagnetic induction, whereby a brief magnetic field is generated within a plastic-coated coil of wire that is placed on the head above the cortical area to be stimulated. The magnetic field passes painlessly through the skull and induces a weak electrical current within the underlying region of cortex. As a result, the neural excitability of the stimulated region may be temporarily altered. The first study to assess the effect of repetitive TMS on visual function in adult with amblyopia demonstrated a transient improvement in contrast sensitivity [65]. TMS is expected to enhance the effects of traditional amblyopia treatments [65-67]. The effects of repeated applications of TMS as a therapeutic option in amblyopia are currently being investigated.

Pharmacologic therapy

Dopamine concentrations have been found to be decreased in the retina with deprivation amblyopia [68]. Increasing retinal dopamine concentrations may have a beneficial effect in amblyopia. In the first study using levodopa, the immediate metabolic precursor of dopamine, as a possible treatment in adult amblyopia, a single administration of levodopa temporarily improved contrast sensitivity and decreased scotoma size in the amblyopic eye [69]. A PEDIG randomized trial of levodopa as a treatment for residual amblyopia in children aged 7 to 12 years showed that treatment with oral levodopa while continuing to patch for 2 hours daily did not produce a clinically or statistically meaningful improvement in VA compared to placebo and patching [70]. Cytidine diphosphatecholine is a complex organic molecule that acts as an intermediate in the biosynthesis of cell membrane phospholipids and has been hypothesized to protect the anatomic and structural integrity of cell membranes, thereby preventing nerve cell damage [71-73]. A study with adult amblyopic patients demonstrated improvement in VA with citicoline augmentation of patching that was not sustained following cessation of the medication [71,72]. Early studies in amblyopic children were promising, showing treatment effects with citicoline both alone and in addition to patching [73]. Potential long-term effects of using levodopa and other medications with psychoactive and extrapyramidal effects in an immature nervous system of children are of concern [74]. Restoring cortical plasticity and reducing interocular suppression have received attention as novel therapeutic strategies for amblyopia [75-79].

Follow-up and Cessation of Amblyopia Treatment

The response to amblyopia treatment should be monitored and the treatment plan should be adjusted as necessary: VA in the amblyopic eye and fellow eye, refraction in both eyes, adherence to the prescribed treatment, and treatment-related side effects should be included in follow-up examinations. Follow-up assessments are usually arranged at six week intervals after initiating amblyopia treatment. Based on the results of previous studies, amblyopia treatment is typically initiated using spectacles alone,
followed by the addition of low-dose patching or weekend atropine in a stepwise manner. If VA in the amblyopic eye has been improving with stable VA in the fellow eye, the current treatment may be continued. If no further improvement in VA is found and residual amblyopia persists in spite of good adherence to treatment, increasing treatment intensity (for example, increasing patching from 2 to 6 hours daily) or changing/adding a treatment modality (for example, switching to topical atropine administration) should be considered. An alternative diagnosis compatible with decreased vision should be considered for children who fail to show any improvement in VA after amblyopia treatment. Thorough ophthalmologic re-examinations should be performed to rule out any organic disorders, such as inherited retinal dystrophy or optic nerve/macular abnormalities.

Although amblyopia can be successfully treated by optical correction, patching, and atropine penalization, recurrence of amblyopia has been reported, with incidences ranging from 6% to 67% [80-83]. In a PEDIG prospective observational study of successfully treated amblyopic children less than 8 years of age for whom treatment had been discontinued, the overall amblyopia incidence of recurrence was 24% over 1 year of follow-up [80]. Recurrence was similar among those patients who discontinued patching (25%) and those who stopped atropine (21%). Recurrence occurred throughout the 52-week follow-up period, although recurrences occurred more frequently during the first 13 weeks after cessation of treatment. In patients treated with moderately intense patching (6 to 8 hours per day), recurrence was more common (42%) when treatment was not reduced prior to cessation than when treatment was reduced to 2 hours per day prior to cessation (14%).

When maximum VA is achieved, treatment should be tapered and then discontinued with monitoring for amblyopia recurrence. De Weger et al. [84] have recommended the follow-up period be longer than 2 years in the presence of risk factors such as increasing anisometropia. Clinicians should be aware of the possibility of vision deterioration after cessation of amblyopia treatment. Careful and prolonged follow-up is needed for all children who have been successfully completed previous treatment for amblyopia [80,83-85].

**Conclusion**

Amblyopia may be reversible with appropriate visual stimulation. The detection and management of amblyopia should begin as early as possible. Several studies have shown that older children and adults with amblyopia also respond to amblyopia treatment. Thus, treatment should be attempted in older children.

Amblyopia should be treated in a stepwise manner (Fig. 1).

---

**Fig. 1.** A stepwise approach to treating childhood amblyopia. VA = visual acuity.
### Table 1. Summary of the results from Pediatric Eye Disease Investigator Group studies

| Published year | Age (yr) | Subtype of amblyopia | Baseline VA in amblyopic eye | Treatment modalities | Results and conclusions |
|----------------|----------|----------------------|-----------------------------|----------------------|------------------------|
| 2007           | <10      | Bilateral refractive | 20 / 40 to 20 / 400         | Spectacles alone     | Treatment of bilateral refractive amblyopia with spectacle correction improved binocular VA, with most improving to 20 / 25 or better within one year [13] |
| 2006           | 3<7      | Anisometropic        | 20 / 40 to 20 / 250         | Spectacles alone     | Amblyopia improved with optical correction by ≥2 lines in 77% of the patients [15] |
| 2005           | 7<17     | Anisometropic or strabismic | 20 / 40 to 20 / 400     | Spectacles alone     | Amblyopia improved with optical correction alone in about one fourth of patients aged 7 to 17 years [16] |
| 2007           | 4<6      | Strabismic           | 20 / 40 to 20 / 250         | Spectacles alone     | Amblyopic eye acuity improved by 2 lines or more from spectacle-corrected baseline acuity in 75% [17] |
| 2010           | 3<7      | Strabismic or Combined | 20 / 40 to 20 / 400        | Spectacles alone     | Optical treatment alone resulted in clinically meaningful improvement in amblyopic eye VA, resolving in at least one fourth of patients without the need for additional treatment [18] |
| 2003           | 3<7      | Anisometropic or strabismic | 20 / 100 to 20 / 400      | Full time patching  | Six hours daily patching produced an improvement in VA that was of similar magnitude to the improvement produced by prescribed full-time patching [19] |
| 2003           | 3<7      | Anisometropic or strabismic | 20 / 40 to 20 / 80        | 6 hours patching    | Two hours of daily patching produced an improvement in VA that was of similar magnitude to the improvement produced by 6 hours of daily [20] |
| 2008           | 3<7      | Anisometropic or strabismic | 20 / 40 to 20 / 400      | 2 hours patching + near vs. distance activities | Performing common near activities did not improve VA outcome when treating amblyopia with 2 hours of daily patching [21] |
| 2013           | 3<8      | Anisometropic or strabismic | Residual amblyopia after 2 hours patching 20 / 32 to 20 / 160 | Continue 2 hours patching vs. increase patching time to 6 hr/day | Improvement of ≥2 lines occurred in 40% of participants patched for 6 hours versus 18% of those who continued to patch for 2 hours [22] |
| 2004           | 3<7      | Anisometropic or strabismic | 20 / 40 to 20 / 80        | Daily atropine vs. weekend atropine | Weekend atropine provided an improvement in VA of a magnitude similar to that of the improvement provided by daily atropine when treating moderate amblyopia [27] |
| 2002           | 3<7      | Anisometropic or strabismic | 20 / 40 to 20 / 100       | Atropine vs. patching | Improvement was initially faster in the patching group, but after 6 months, the between-group difference in VA was small and clinically inconsequential. Atropine and patching produce improvement of similar magnitude [30] |
| 2009           | 3<7      | Anisometropic or strabismic | 20 / 125 to 20 / 400      | Weekend atropine    | Weekend atropine improved VA in children with severe amblyopia [31] |
| 2004           | 10<18    | Anisometropic or strabismic | 20 / 40 to 20 / 160       | Daily patching (≥2 hours a day) combined with at least 1 hour of near activities | VA improved ≥2 lines from baseline in 27% of the 66 patients and the improvement appeared similar in 10- to <14-year-olds and 14- to <18-year-olds [39] |
| 2004           | <8       | Anisometropic or strabismic | Successfully treated amblyopia with patching or atropine | | Approximately one fourth of successfully treated amblyopic children experienced a recurrence within the first year of treatment. Risk of recurrence was greater when patching was stopped abruptly rather than when it was reduced to 2 hours per day prior to cessation [80] |

VA = visual acuity.
The results from various PEDIG studies are summarized in Table 1 [13,15-22,27,30,31,39,80]. Prescribing an appropriate refractive correction is an initial step when treating amblyopic patients. Patching for 2 hours each day or pharmacologic penalization may be considered as an additional treatment option for amblyopia. If there is no improvement between two consecutive visits, increasing the prescribed patching duration to 6 hours per day could be a reasonable option. Good compliance with prescribed amblyopia treatment is critical for a successful visual outcome. Compliance with amblyopia therapy may be improved by educational programs, direct communication with children and their parents, and increasing the frequency of follow-up visits. Treatment should be tapered and then discontinued with monitoring for amblyopia recurrence. Follow-up visits are required after cessation of treatment to detect any deterioration of vision and provide prompt re-treatment, if necessary.

**Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

**References**

1. Wallace DK, Repka MX, Lee KA, et al. Amblyopia preferred practice pattern. *Ophthalmology* 2018;125:5105-42.
2. Weinacht S, Kind C, Monting JS, Gottlob I. Visual development in preterm and full-term infants: a prospective masked study. *Invest Ophthalmol Vis Sci* 1999;40:346-53.
3. Daw NW. Critical periods and amblyopia. *Arch Ophthalmol* 1998;116:502-5.
4. Gaier ED, Hunter DG. Advances in amblyopia treatment: paradigm shifts and future directions. *Int Ophthalmol Clin* 2017;57:117-28.
5. Eibschitz-Tsimhoni M, Friedman T, Naor J, et al. Early screening for amblyogenic risk factors lowers the prevalence and severity of amblyopia. *J AAPOS* 2000;4:194-9.
6. Kvarnstrom G, Jakobssson P, Lennerstrand G. Visual screening of Swedish children: an ophthalmological evaluation. *Acta Ophthalmol Scand* 2001;79:240-4.
7. Chang JH. Infant and toddler vision care: a supplement to the manual of infant health screening conducted by Korean National Health Insurance Corporation. *J Korean Med Assoc* 2013;56:504-10.
8. Blakemore C, van Sluyters RC. Reversal of the physiological effects of monocular deprivation in kittens: further evidence for a sensitive period. *J Physiol* 1974;237:195-216.
9. Rauschecker JP, Schrader W, von Grunau MW. Rapid recovery from monocular deprivation in kittens after specific visual training. *Clin Vis Sci* 1987;1:257-68.
10. Mohan K, Saroha V, Sharma A. Successful occlusion therapy for amblyopia in 11- to 15-year-old children. *J Pediatr Ophthalmol Strabismus* 2004;41:89-95.
11. Holmes JM, Lazar EL, Melia BM, et al. Effect of age on response to amblyopia treatment in children. *Arch Ophthalmol* 2011;129:1451-7.
12. Wallace DK, Morse CL, Melia M, et al. Pediatric Eye Evaluations Preferred Practice Pattern: I. vision screening in the primary care and community setting; II. comprehensive ophthalmic examination. *Ophthalmology* 2018;125:184-227.
13. Wallace DK, Chandler DL, Beck RW, et al. Treatment of bilateral refractive amblyopia in children three to less than 10 years of age. *Am J Ophthalmol* 2007;144:487-96.
14. Moseley MJ, Neufeld M, McCarr B, et al. Remediation of refractive amblyopia by optical correction alone. *Ophthalmic Physiol Opt* 2002;22:296-9.
15. Cotter SA; Pediatric Eye Disease Investigator Group, Edwards AR, et al. Treatment of anisometropic amblyopia in children with refractive correction. *Ophthalmology* 2006;113:895-903.
16. Scheiman MM, Hertle RW, Beck RW, et al. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. *Arch Ophthalmol* 2005;123:437-47.
17. Cotter SA, Edwards AR, Arnold RW, et al. Treatment of strabismic amblyopia with refractive correction. *Am J Ophthalmol* 2007;143:1060-3.
18. Writing Committee for the Pediatric Eye Disease Investigator Group, Cotter SA, Foster NC, et al. Optical treatment of strabismic and combined strabismic-anisometropic amblyopia. *Ophthalmology* 2012;119:150-8.
19. Holmes JM, Kraker RT, Beck RW, et al. A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. *Ophthalmology* 2003;110:2075-87.
20. Repka MX, Beck RW, Holmes JM, et al. A randomized trial of patching regimens for treatment of moderate amblyopia in children. *Arch Ophthalmol* 2003;121:603-11.
21. Pediatric Eye Disease Investigator Group. A randomized
trial of near versus distance activities while patching for amblyopia in children aged 3 to less than 7 years. *Ophthalmology* 2008;115:2071-8.

22. Pediatric Eye Disease Investigator Group, Wallace DK, Lazar EL, et al. A randomized trial of increasing patching for amblyopia. *Ophthalmology* 2013;120:2270-7.

23. Wallace DK, Lazar EL, Crouch ER 3rd, et al. Time course and predictors of amblyopia improvement with 2 hours of daily patching. *JAMA Ophthalmol* 2015;133:606-9.

24. Brown MH, Edelman PM. Conventional occlusion in the older amblyope. *Am Orthopt J* 1976;26:34-6.

25. Koc F, Ozal H, Yasar H, Firat E. Resolution in partially accommodative esotropia during occlusion treatment for amblyopia. *Eye (Lond)* 2006;20:325-8.

26. Repka MX, Holmes JM, Melia BM, et al. The effect of amblyopia therapy on ocular alignment. *J AAPOS* 2005;9:542-5.

27. Repka MX, Cotter SA, Beck RW, et al. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. *Ophthalmology* 2004;111:2076-85.

28. Pediatric Eye Disease Investigator Group. The course of moderate amblyopia treated with atropine in children: experience of the amblyopia treatment study. *Am J Ophthalmol* 2003;136:630-9.

29. Repka MX, Wallace DK, Beck RW, et al. Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. *Arch Ophthalmol* 2005;123:149-57.

30. Pediatric Eye Disease Investigator Group. A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children. *Arch Ophthalmol* 2002;120:268-78.

31. Repka MX, Kraker RT, Beck RW, et al. Treatment of severe amblyopia with weekend atropine: results from 2 randomized clinical trials. *J AAPOS* 2009;13:258-63.

32. Simons K, Gotzler KC, Vitale S. Penalization versus part-time occlusion and binocular outcome in treatment of strabismic amblyopia. *Ophthalmology* 1997;104:2156-60.

33. Nishizawa AR, Orton RB, Cadera W. Comparison of 0.5% cyclopentolate plus 0.5% tropicamide and 1% cyclopentolate alone for mydriasis of dark irides. *Can J Ophthalmol* 1988;23:299-300.

34. Park SH, Park SM, Cho AR, Park SH. Pharmacologic effects of atropine penalization in amblyopic eyes. *J Korean Ophthalmol Soc* 2014;55:590-5.

35. Repka MX, Kraker RT, Holmes JM, et al. Atropine vs patching for treatment of moderate amblyopia: follow-up at 15 years of age of a randomized clinical trial. *JAMA Ophthalmol* 2014;132:799-805.

36. Quah BL, Tay MT, Chew SJ, Lee LK. A study of amblyopia in 18-19 year old males. *Singapore Med J* 1991;32:126-9.

37. Epelbaum M, Milleret C, Buisseret P, Dufler JL. The sensitive period for strabismic amblyopia in humans. *Ophthalmology* 1993;100:323-7.

38. Simmers AJ, Gray LS. Improvement of visual function in an adult amblyope. *Optom Vis Sci* 1999;76:82-7.

39. Pediatric Eye Disease Investigator Group. A prospective, pilot study of treatment of amblyopia in children 10 to <18 years old. *Am J Ophthalmol* 2004;137:581-3.

40. Lee YR, Lee JY. Part-time occlusion therapy for anisotropic amblyopia detected in children eight years of age and older. *Korean J Ophthalmol* 2006;20:171-6.

41. Wallace MP, Stewart CE, Moseley MJ, et al. Compliance with occlusion therapy for childhood amblyopia. *Invest Ophthalmol Vis Sci* 2013;54:6158-66.

42. Vagge A, Nelson LB. Compliance with the prescribed occlusion treatment for amblyopia. *Curr Opin Ophthalmol* 2017;28:454-9.

43. Newsham D. Parental non-concordance with occlusion therapy. *Br J Ophthalmol* 2000;84:957-62.

44. Newsham D. A randomised controlled trial of written information: the effect on parental non-concordance with occlusion therapy. *Br J Ophthalmol* 2002;86:787-91.

45. Sachdeva V, Mittal V, Kekunnaya R, et al. Efficacy of split hours part-time patching versus continuous hours part-time patching for treatment of anisometropic amblyopia in children: a pilot study. *Br J Ophthalmol* 2013;97:874-8.

46. Kim SJ, Jeon H, Jung JH, et al. Comparison between over-glasses patching and adhesive patching for children with moderate amblyopia: a prospective randomized clinical trial. *Graefes Arch Clin Exp Ophthalmol* 2018;256:429-37.

47. Wang J, Jin J, Malik A, et al. Feasibility of monitoring compliance with intermittent occlusion therapy glasses for amblyopia treatment. *J AAPOS* 2019;23:205.

48. Spierer A, Raz J, Benezra O, et al. Treating amblyopia with liquid crystal glasses: a pilot study. *Invest Ophthalmol Vis Sci* 2010;51:3395-8.

49. Erbagci I, Okumus S, Oner V, et al. Using liquid crystal glasses to treat amblyopia in children. *J AAPOS* 2015;19:257-9.

50. Wang J, Neely DE, Galli J, et al. A pilot randomized clinical trial of intermittent occlusion therapy liquid crystal
glasses versus traditional patching for treatment of moderate unilateral amblyopia. J AAPOS 2016;20:326-31.
51. Gibson EJ. Perceptual learning. *Annu Rev Psychol* 1963;14:29-56.
52. Polat U. Restoration of underdeveloped cortical functions: evidence from treatment of adult amblyopia. *Restor Neurol Neurosci* 2008;26:413-24.
53. Campbell FW, Hess RF, Watson PG, Banks R. Preliminary results of a physiologically based treatment of amblyopia. *Br J Ophthalmol* 1978;62:748-55.
54. Levi DM, Polat U, Hu YS. Improvement in Vernier acuity in adults with amblyopia. Practice makes better. *Invest Ophthalmol Vis Sci* 1997;38:1493-510.
55. Polat U, Ma-Naim T, Belkin M, Sagi D. Improving vision in adult amblyopia by perceptual learning. *Proc Natl Acad Sci U S A* 2004;101:6692-7.
56. Xi J, Jia WL, Feng LX, et al. Perceptual learning improves stereoacuity in amblyopia. *Invest Ophthalmol Vis Sci* 2014;55:2384-91.
57. Hess RF, Mansouri B, Thompson B. A new binocular approach to the treatment of amblyopia in adults well beyond the critical period of visual development. *Restor Neurol Neurosci* 2010;28:793-802.
58. Knox PJ, Simmers AJ, Gray LS, Cleary M. An exploratory study: prolonged periods of binocular stimulation can provide an effective treatment for childhood amblyopia. *Invest Ophthalmol Vis Sci* 2012;53:817-24.
59. Birch EE, Li SL, Jost RM, et al. Binocular iPad treatment for amblyopia in preschool children. *J AAPOS* 2015;19:6-11.
60. Holmes JM, Manh VM, Lazar EL, et al. Effect of a binocular iPad game vs part-time patching in children aged 5 to 12 years with amblyopia: a randomized clinical trial. *JAMA Ophthalmol* 2016;134:1391-400.
61. Kelly KR, Jost RM, Dao L, et al. Binocular iPad game vs patching for treatment of amblyopia in children: a randomized clinical trial. *JAMA Ophthalmol* 2016;134:1402-8.
62. Manh VM, Holmes JM, Lazar EL, et al. A randomized trial of a binocular iPad game versus part-time patching in children aged 13 to 16 years with amblyopia. *Am J Ophthalmol* 2018;186:104-15.
63. Pediatric Eye Disease Investigator Group, Holmes JM, Manny RE, et al. A randomized trial of binocular Dig Rush game treatment for amblyopia in children aged 7 to 12 years. *Ophthalmology* 2019;126:456-66.
64. Gao TY, Guo CX, Babu RJ, et al. Effectiveness of a binocular video game vs placebo video Game for improving visual functions in older children, teenagers, and adults with amblyopia: a randomized clinical trial. *JAMA Ophthalmol* 2018;136:172-81.
65. Barker AT, Jalinos R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. *Lancet* 1985;1:1106-7.
66. Hess RF, Thompson B. New insights into amblyopia: binocular therapy and noninvasive brain stimulation. *J AAPOS* 2013;17:89-93.
67. Thompson B, Mansouri B, Koski L, Hess RF. Brain plasticity in the adult: modulation of function in amblyopia with rTMS. *Curr Biol* 2008;18:1067-71.
68. Iuvone PM, Tigges M, Fernandes A, Tigges J. Dopamine synthesis and metabolism in rhesus monkey retina: development, aging, and the effects of monocular visual deprivation. *Vis Neurosci* 1989;2:465-71.
69. Gottlob I, Stangler-Zuschrott E. Effect of levodopa on contrast sensitivity and scotomas in human amblyopia. *Invest Ophthalmol Vis Sci* 1990;31:776-80.
70. Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, et al. A randomized trial of levodopa as treatment for residual amblyopia in older children. *Ophthalmology* 2015;122:874-81.
71. Pawar PV, Mumbare SS, Patil MS, Ramakrishnan S. Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial. *Indian J Ophthalmol* 2014;62:124-9.
72. Campos EC, Bolzani R, Schiavi C, et al. Cytidin-5'-diphosphocholine enhances the effect of part-time occlusion in amblyopia. *Doc Ophthalmol* 1996-1997;93:247-63.
73. Campos EC, Schiavi C, Benedetti P, et al. Effect of citicoline on visual acuity in amblyopia: preliminary results. *Graefes Arch Clin Exp Ophthalmol* 1995;233:307-12.
74. Razeghinejad MR, Nowroozzadeh MH, Eghbali MH. Levodopa and other pharmacologic interventions in ischemic and traumatic optic neuropathies and amblyopia. *Clin Neuropharmacol* 2016;39:40-8.
75. Putignano E, Lonetti G, Canciedda L, et al. Developmental downregulation of histone posttranslational modifications regulates visual cortical plasticity. *Neuron* 2007;53:747-59.
76. Smith GB, Bear MF. Bidirectional ocular dominance plasticity of inhibitory networks: recent advances and unresolved questions. *Front Cell Neurosci* 2010;4:21.
77. Wong AM. New concepts concerning the neural mechanisms of amblyopia and their clinical implications. *Can J Ophthalmol* 2012;47:399-409.
78. Tsirlin I, Colpa L, Goltz HC, Wong AM. Behavioral training
as new treatment for adult amblyopia: a meta-analysis and systematic review. *Invest Ophthalmol Vis Sci* 2015;56:4061-75.

79. Vagge A, Nelson LB. Amblyopia update: new treatments. *Curr Opin Ophthalmol* 2016;27:380-6.

80. Holmes JM, Beck RW, Kraker RT, et al. Risk of amblyopia recurrence after cessation of treatment. *J AAPOS* 2004;8:420-8.

81. Rutstein RP, Fuhr PS. Efficacy and stability of amblyopia therapy. *Optom Vis Sci* 1992;69:747-54.

82. Scott WE, Dickey CF. Stability of visual acuity in amblyopic patients after visual maturity. *Graefes Arch Clin Exp Ophthalmol* 1988;226:154-7.

83. Gunton KB. Advances in amblyopia: what have we learned from PEDIG trials? *Pediatrics* 2013;131:540-7.

84. De Weger C, Van Den Brom HJ, Lindeboom R. Termination of amblyopia treatment: when to stop follow-up visits and risk factors for recurrence. *J Pediatr Ophthalmol Strabismus* 2010;47:338-46.

85. Holmes JM, Melia M, Bradfield YS, et al. Factors associated with recurrence of amblyopia on cessation of patching. *Ophthalmology* 2007;114:1427-32.